SCHEMBL4609429

SCHEMBL4609429

CCN1CCC(C(CS(=O)(=O)N2CCN(c3ccccc3C)CC2)C(=O)NO)CC1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
MAPK1 P28482 1/20 0.44
ADAM10 O14672 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
OXTR P30559 5/20 0.41
AVPR2 P30518 2/20 0.41
AVPR1A P37288 2/20 0.41
CYP3A4 P08684 1/20 0.41
LMNA P02545 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
OPRK1 P41145 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
AVPR1B P47901 1/20 0.41
HSD17B10 Q99714 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4609431 1.00 TSHR (0.44) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL4610406 0.91 TSHR (0.45) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL4610407 0.91 TSHR (0.45) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL4612474 0.88 ADAM10 (0.42) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL4610016 0.88 ADAM10 (0.50) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL6033492 0.88 ADAM10 (0.50) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL4612477 0.88 ADAM10 (0.42) TSHRMAPK1ADAM10MEN1KMT2A
SCHEMBL4609379 0.85 ADAM10 (0.46) TSHRMAPK1ADAM10PKM
SCHEMBL4609370 0.85 ADAM10 (0.46) TSHRMAPK1ADAM10PKM
SCHEMBL4610349 0.78 MAPK1 (0.47) TSHRMAPK1ADAM10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641771-B1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS UCB PHARMA SA (BE) 2008-10-15 EP disclosed
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CELLTECH R&D LIMITED (GB) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241118-A1 Hydroxamate sulfonamides as cd23 shedding inhibitors CD22, CD2, DPP3 TSHR 1840/4885MAPK1 4175/4885ADAM10 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.